Trial Profile
Malaria Chemoprevention With Monthly Treatment With Dihydroartemisinin-piperaquine for the Post-discharge Management of Severe Anaemia in Children Aged Less Than 5 Years in Uganda and Kenya: A Two-arm Randomised Placebo Controlled Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Dec 2020
Price :
$35
*
At a glance
- Drugs Dihydroartemisinin/piperaquine (Primary)
- Indications Malaria
- Focus Therapeutic Use
- Acronyms PMC
- 03 Dec 2020 Primary endpoint, All-cause deaths or all-cause re-admissions by 26 weeks from randomization (composite primary outcome, has been met as per results published in the New England Journal of Medicine
- 03 Dec 2020 Results published in the New England Journal of Medicine
- 02 Jun 2020 Status changed from recruiting to completed.